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Objective
Migraine prevention guidelines recommend oral
migraine preventive medications (OMPMs) for patients
with frequent headache, such as chronic migraine (CM).
We sought to understand OMPM treatment patterns by
evaluating persistence, medication switching, and medi-
cation re-initiation among CM pa
Methods
A retrospective claims analysis was undertaken using the
MarketScan® Databases. The analysis included patients
≥18 years old, with a CM diagnosis, who initiated an
OMPM between January 1, 2008 and September 30, 2012.
Patient persistence was measured at 6 and 12 months.
Time to discontinuation was assessed for each OMPM and
compared using Cox regression models. Among those who
discontinued, we also assessed the proportion of patients
who switched to another OMPM within 60 days or re-
initiated treatment with OMPMs between 61 to 365 days.
Results
A total of 8,707 patients met the inclusion/exclusion cri-
teria. Persistence with the initial OMPM was 25% at 6
months and 14% at 12 months. Amitriptyline, nortripty-
line, and gabapentin had significantly higher likelihood of
discontinuation when compared to topiramate. Of patients
who discontinued, approximately 23% switched to another
prophylactic and another 41% reinitiated therapy within
one year. Among patients who switched, 12-month persis-
tence was 13% to the second prophylactic and 10% for the
third. Among reinitiated patients this rate was 8% and 4%,
respectively.
Conclusion
Persistence to OMPMs is poor among the US CM
population at 6 months and declines further by 12
months. After initial discontinuation, switching or re-
initiating is common; however, persistence declines as
patients cycle through various OMPMs.
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